Jump to content

Lamivudine/nevirapine/zidovudine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doc James (talk | contribs) at 10:15, 3 May 2020. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lamivudine/nevirapine/zidovudine
Combination of
Lamivudinenucleoside reverse transcriptase inhibitor
Nevirapinenon-nucleoside reverse transcriptase inhibitor
Zidovudinenucleoside reverse transcriptase inhibitor
Clinical data
Trade namesDuovir-N, Zidovex-LN, others[1]
ATC code
Identifiers
ChemSpider
  • none

Lamivudine/nevirapine/zidovudine (3TC/NVP/AZT) is a medication used to treat HIV/AIDS.[2] It is a fixed dose combination of lamivudine, nevirapine, and zidovudine.[2] It is either used by itself or along with other antiretrovirals.[2] It is a recommended treatment in those who are pregnant.[2] It is taken by mouth twice a day.[2]

The medication is generally well tolerated.[1] Side effects are those of the underlying medications.[2] This includes rash, pancreatitis, low white blood cell levels, and muscle pain.[1] Use is not recommended in those with significant liver problems.[1] Use in pregnancy and breastfeeding appear to be safe.[1] The combination tablet is typically not appropriate for children.[2]

It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[3] The wholesale cost in the developing world is about 8.54 to 18.94 USD a month as of 2014.[4] The combination is not commercially available in the United States as of 2018.[5]

See also

References

  1. ^ a b c d e "Nevirapine, zidovudine and lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
  2. ^ a b c d e f g World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. pp. 157, 161. hdl:10665/44053. ISBN 9789241547659.
  3. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ^ "Lamivudine + Zidovudine + Nevirapine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
  5. ^ "Drugs@FDA: FDA Approved Drug Products". www.accessdata.fda.gov. Retrieved 6 January 2018.